Health
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) – Business Wire
Moderna announces publication of interim results from older adult age cohorts in Phase 1 study of its mRNA vaccine in NEJM.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, inThe New England Journal of Medicine. This interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart…
-
Noosa News10 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News10 hours agoBoy charged over E-Bike crash
-
Noosa News15 hours agoLarge fleet of Robinson R22 helicopters sold as HM Air flies in another direction
-
General8 hours agoCrowe toasts talkback titan for platforming ‘voiceless’